Home
About
- Our Team
- Careers
News
Contact

Technology
Diagnostics
Therapeutics
- Drug Discovery
- Safer Drugs
Products
- Sales
- Licensing & Distribution
Services
Resources

AmberGen receives US Patent 8,114,587 for analyzing DNA mutations in fecal samples for colorectal cancer detection

February 2012/in News, PIONEERING NEW TECHNOLOGIES /by Kenneth Rothschild

Share this entry

http://www.ambergen.com/wp-content/uploads/logo-retina.png 0 0 Kenneth Rothschild http://www.ambergen.com/wp-content/uploads/logo-retina.png Kenneth Rothschild2012-02-27 13:46:482016-11-10 12:44:59AmberGen receives US Patent 8,114,587 for analyzing DNA mutations in fecal samples for colorectal cancer detection

Menu

Home
About
Technology
Diagnostics
Therapeutics

Products
Services
Resources
News
Contact

Get in Touch

AmberGen, Inc.

313 Pleasant St.

Watertown, MA 02472

(617) 932-9990

info@ambergen.com

Recent News

Recent Posts

AmberGen receives US Patent 9,910,034 increasing its broad coverage on PC-PURE™ photo-affinity biomarker purification and enrichment technology for improving the accuracy of diagnostic testing March 2018
Paper published in PLOS ONE in collaboration with Boston Children’s Hospital “Photocleavage-based affinity purification of biomarkers from serum: Application to multiplex allergy testing” describing application of AmberGen’s PC-PURE™ to highly multiplex in vitro allergy testing (AllerBead™) February 2018

© 2018 - AmberGen Inc. Website designed in Massachusetts

Agreement between AmberGen and SomaLogic® enables use of photocleavable reagent... AmberGen awarded Phase I SBIR grant for development of a multiplex in vitro...

Scroll to top